Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

医学 安慰剂 双盲 内科学 物理疗法 儿科 病理 替代医学
作者
Benedikt Schoser,Mark Roberts,Barry J. Byrne,Sheela Sitaraman,Hai Jiang,Pascal Laforêt,António Toscano,Jeff Castelli,Jordi Díaz‐Manera,Mitchell Goldman,Ans T. van der Ploeg,Drago Bratkovic,Suresh V. Kuchipudi,Tahseen Mozaffar,Priya S. Kishnani,Ágnes Sebők,Alan Pestronk,Aleksandra Dominović-Kovačević,Anzalee Khan,Blaž Koritnik,Céline Tard,Christopher Lindberg,Colin Quinn,Cornelia Kornblum,Crystal Eldridge,Cynthia Bodkin,David Reyes‐Leiva,Derralynn Hughes,Ela Stefanescu,Emmanuelle Salort‐Campana,Ernest Butler,Françoise Bouhour,Gee Kim,George K. Papadimas,Giancarlo Parenti,Halina Bartosik-Psujek,Hani Kushlaf,Akihiro Hashiguchi,Heather Lau,Hélio Pedro,Henning Andersen,Hernán Amartino,Hideaki Shiraishi,Hiroshi Kobayashi,Ivaylo Tarnev,Jaime Vengoechea,Jennifer Avelar,Jin‐Hong Shin,Jonathan Cauci,Jorge Alonso‐Pérez,József Janszky,Julie Berthy,Kristina Gutschmidt,Kristl G. Claeys,Mária Judit Molnár,Marie Wencel,Mark A. Tarnopolsky,Mazen M. Dimachkie,Michel Tchan,Miriam Freimer,Nicola Longo,Nuria Vidal-Fernandez,Olimpia Musumeci,Özlem Göker-Alpan,Patrick Deegan,Paula R. Clemens,Richard Roxburgh,Robert Henderson,Robert J. Hopkin,Sabrina Sacconi,Simona Fecarotta,Shahram Attarian,Stephan Wenninger,Stephanie DeArmey,Tarekegn Hiwot,Thomas Andrew Burrow,Tobias Ruck,Tomo Sawada,Vescei Laszlo,Wolfgang N. Löscher,Yin‐Hsiu Chien
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:20 (12): 1027-1037 被引量:75
标识
DOI:10.1016/s1474-4422(21)00331-8
摘要

Pompe disease is a rare disorder characterised by progressive loss of muscle and respiratory function due to acid α-glucosidase deficiency. Enzyme replacement therapy with recombinant human acid α-glucosidase, alglucosidase alfa, is the first approved treatment for the disease, but some patients do not respond, and many do not show a sustained benefit. We aimed to assess the safety and efficacy of an investigational two-component therapy (cipaglucosidase alfa, a novel recombinant human acid α-glucosidase, plus miglustat, an enzyme stabiliser) for late-onset Pompe disease.We did a randomised, double-blind, parallel-group, phase 3 trial at 62 neuromuscular and metabolic medical centres in 24 countries in the Americas, Asia-Pacific, and Europe. Eligible participants were aged 18 years or older with late-onset Pompe disease, and had either been receiving alglucosidase alfa for at least 2 years or were enzyme replacement therapy-naive. Participants were randomly assigned (2:1) using interactive response technology software, stratified by 6-min walk distance and previous enzyme replacement therapy status, to intravenous cipaglucosidase alfa (20 mg/kg) plus oral miglustat or to intravenous alglucosidase alfa (20 mg/kg) plus oral placebo once every 2 weeks for 52 weeks. Patients, investigators, and outcome assessors were masked to treatment assignment. The primary endpoint was change from baseline to week 52 in 6-min walk distance, assessed using a mixed-effect model for repeated measures analysis for comparison of superiority in the intention-to-treat population (all patients who received at least one dose of study drug). This study is now complete and is registered with ClinicalTrials.gov, NCT03729362.Between Dec 3, 2018, and Nov 26, 2019, 130 patients were screened for eligibility and 125 were enrolled and randomly assigned to receive cipaglucosidase alfa plus miglustat (n=85) or alglucosidase alfa plus placebo (n=40). Two patients in the alglucosidase alfa plus placebo group did not receive any dose due to absence of genotype confirmation of late-onset Pompe disease and were excluded from analysis. Six patients discontinued (one in the alglucosidase alfa plus placebo group, five in the cipaglucosidase alfa plus miglustat group), and 117 completed the study. At week 52, mean change from baseline in 6-min walk distance was 20·8 m (SE 4·6) in the cipaglucosidase alfa plus miglustat group versus 7·2 m (6·6) in the alglucosidase alfa plus placebo group using last observation carried forward (between-group difference 13·6 m [95% CI -2·8 to 29·9]). 118 (96%) of 123 patients experienced at least one treatment-emergent adverse event during the study; the incidence was similar between the cipaglucosidase alfa plus miglustat group (n=81 [95%]) and the alglucosidase alfa plus placebo group (n=37 [97%]). The most frequently reported treatment-emergent adverse events were fall (25 [29%] patients in the cipaglucosidase alfa plus miglustat group vs 15 [39%] in the alglucosidase alfa plus placebo group), headache (20 [24%] vs 9 [24%]), nasopharyngitis (19 [22%] vs 3 [8%]), myalgia (14 [16%] vs 5 [13%]), and arthralgia (13 [15%]) vs 5 [13%]). 12 serious adverse events occurred in eight patients in the cipaglucosidase alfa plus miglustat group; only one event (anaphylaxis) was deemed related to study drug. One serious adverse event (stroke) occurred in the alglucosidase alfa plus placebo group, which was deemed unrelated to study drug. There were no deaths.Cipaglucosidase alfa plus miglustat did not achieve statistical superiority to alglucosidase alfa plus placebo for improving 6-min walk distance in our overall population of patients with late-onset Pompe disease. Further studies should investigate the longer-term safety and efficacy of cipaglucosidase alfa plus miglustat and whether this investigational two-component therapy might provide benefits, particularly in respiratory function and in patients who have been receiving enzyme replacement therapy for more than 2 years, as suggested by our secondary and subgroup analyses.Amicus Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
陶醉的翠霜完成签到 ,获得积分10
刚刚
刚刚
冷静如松完成签到 ,获得积分10
7秒前
9秒前
浮云完成签到 ,获得积分10
10秒前
屈岂愈完成签到,获得积分10
11秒前
25秒前
Pupil完成签到,获得积分10
25秒前
偏偏意气用事完成签到,获得积分10
26秒前
安安完成签到,获得积分10
30秒前
cttc完成签到,获得积分10
31秒前
Chnimike完成签到 ,获得积分10
31秒前
35秒前
红茸茸羊完成签到 ,获得积分10
35秒前
年轻千愁完成签到 ,获得积分10
37秒前
liu完成签到,获得积分10
38秒前
量子星尘发布了新的文献求助10
38秒前
Wanyeweiyu完成签到,获得积分10
40秒前
Fury完成签到 ,获得积分10
45秒前
风中幻梦完成签到,获得积分10
47秒前
bigpluto完成签到,获得积分10
48秒前
50秒前
是谁还没睡完成签到 ,获得积分10
51秒前
盘尼西林发布了新的文献求助10
55秒前
zzz完成签到 ,获得积分10
57秒前
dktrrrr完成签到,获得积分10
59秒前
科研通AI2S应助科研通管家采纳,获得10
59秒前
丘比特应助科研通管家采纳,获得20
59秒前
59秒前
ccc完成签到,获得积分10
1分钟前
萧秋灵完成签到,获得积分10
1分钟前
缓慢冥幽完成签到,获得积分10
1分钟前
旺仔同学完成签到,获得积分10
1分钟前
吉以寒完成签到,获得积分10
1分钟前
科研老兵完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
fys131415完成签到 ,获得积分10
1分钟前
执着的忆雪完成签到 ,获得积分10
1分钟前
1分钟前
闵不悔完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022